ALS INVESTMENT FUND INVESTING WITH PURPOSE

WE SUPPORT & FINANCE BIOTECH COMPANIES WHO DEVELOP DRUGS & DIAGNOSTICS FOR THE DISEASE ALS

Our deeply rooted belief is that entrepreneurship in combination with research will drive innovation. The most efficient and proven model, in which entrepreneurs can strive and are incentivized, is the venture capital model. As we are specialized in one disease, we bring in-depth knowledge and an international network to the table.

We invest globally, but our focus is on Europe and the US.

OUR TEAM

We are entrepreneurs and investors who have been involved in several biotech and pharma companies in the rare disease — and ALS space. We know what it takes to bring technologies to the market and make a return for our investors (impact as well as financial return).

The ALS Investment Fund is managed by SUNU Ventures BV, a Dutch limited company.

Qurit Alliance along with several service providers have supported the launch of the fund and will take one Advisory Board seat to represent the patient’s perspective.

ALS INVESTMENT FUND

Felix von Coerper
Melanie Leitner
Craig Boyce

ADVISORY BOARD

Alan Walts
Manfred Rüdiger
Rist Brouwer

SCIENTIFIC ADVISORY BOARD

Leonard van den Berg, UMC Utrecht (NL)
Dr. Jeff Rothstein, Johns Hopkins (USA)
Prof. Pamela Shaw, Univ. of Sheffield (UK)
Lucie Bruijn, PhD
Dr. Robert Brown, UMass (USA)
Dr Merit Cudkowicz, MGH/Harvard (USA)
Dr. Fernando Vieira, ALS TDI (USA)
Dr. Neil Shneider, Columbia (USA)

NEWS

Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Search for cure against the lethal disease ALS boosted by new investor
Orphazyme closes a €14 million Series B Extension
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  
Project ALS and Amylyx Enter Collaboration to Test AMX0035  
Amylyx closes a $ 5 million Series A Investment
Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  
Verge Genomics announces $32 Million Series A to Lead Artificial Intelligence-Driven Drug Discovery

TIMELINE

2019
2018
2018
2018
2017
2017
2017
2017
2016
2016
2016
2016
2015
2015
Q1'19
Q4'18
5th investment: ApicBio
02'18
4th investment: Emulate
Q4'18
Follow - on Amylyx
Q4'17
IPO Orphazyme
Q2'17
1st institutional investor
Q1'17
New partner joins ex managing director Bain Capital
Q1'17
2nd investment: Orphazyme
Q3'16
1st investment of ALS-IF: Amylyx Inc.
Q2'16
First commitments from limited partners
Q2'16
CSO, investment committee and scientific board appointed
Q1'16
Life Sciences Parters advises with set-up
Q3'15
Qurit foundation founded to support initiation of the VC fund
Q2'15
3 ALS patients develop the concept of a VC fund specializing in ALS

ALS Investment Fund I is managed by:

SUNU Ventures
Eerste Weteringdwarsstraat 54E

1017TP Amsterdam, The Netherlands
E: 
contact@alsinvestmentfund.com

Visting address:

Kerkstraat 342, 1017 JA Amsterdam

Copyright ©2018 SUNU Ventures BV – All rights reserved  –  Disclaimer

ALS Investment Fund II is managed by:

SUNU Ventures
182 Beacon Street #14

Boston MA 02116, USA
E: 
contact@alsinvestmentfund.com

Copyright ©2018 SUNU Ventures BV – All rights reserved